Work

Switch rates and total cost associated with apremilast and biologics in biologic-naive patients with psoriatic arthritis

Year: 2021

Type: article

Abstract: Aim: Real-world treatment data for psoriatic arthritis are limited. We evaluated switch rates, adherence, and costs for patients initiating apremilast versus tumor necrosis factor inhibitor (TNFi) and interleukin inhibitor (ILi) among biologic-naive psoriatic arthritis patients. Materials & methods: This retrospective analysis used IBM MarketScan claims data to assess treatment switches, adherence and costs. Results: Twelve-month switch rates were significantly lower for apremilast versus TNFi (15.5% vs 26.6%; p < 0.0001) and similar to ILi (15.5% vs 14.0%; p = 0.71). Apremilast initiators had lower total costs versus TNFi and ILi (US$39,854 vs US$57,243 and US$65,687; p < 0.05) and adherence was slightly lower versus TNFi and higher versus ILi. Conclusion: Biologic-naive apremilast initiators had lower switch rates versus TNFi initiators and lower total costs versus TNFi or ILi initiators.

Source: Journal of Comparative Effectiveness Research

DOI: 10.2217/cer-2020-0285

Authors: David L Kaplan, Brian L Ung, Corey Pelletier, Chuka Udeze, Ibrahim Khilfeh, Marc Tian

Institutions: Adult and Pediatric Dermatology, Bristol-Myers Squibb (United States), Celgene (United States), Amgen (United States)

Language: English

Topic: Spondyloarthritis Studies and Treatments

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funder: Celgene